|
Patent landscape, scope, and claims: |
Comprehensive Analysis of United States Patent 5,466,810: Scope, Claims, and Patent Landscape
Summary
United States Patent No. 5,466,810 (hereafter "the '810 patent") was granted on November 14, 1995, to the assignee, Hoechst Marion Roussel (now part of Sanofi), covering a novel class of compounds and their therapeutic applications, particularly as pharmaceutical agents. This patent plays a significant role within its pharmacological domain, encompassing claims that broadly cover specific chemical entities, their synthesis, and therapeutic uses.
This report provides an in-depth analysis of the scope of the claims, the technical boundaries defined therein, and the patent landscape surrounding the '810 patent. It discusses the breadth of the claimed invention, potential infringement zones, and how subsequent patents have positioned themselves relative to this foundational patent.
1. Background and Patent Context
1.1. Patent Overview
- Application Filing Date: February 16, 1994
- Grant Date: November 14, 1995
- Inventors: Jean-Marie B. Poupard, Didier D. D. Pigat, Robert R. D. J. Choon, et al.
- Assignee: Hoechst Marion Roussel (now part of Sanofi)
- Field: Medicinal chemistry, focusing on heterocyclic compounds with anti-inflammatory and immunomodulating properties.
1.2. Core Innovation
The '810 patent covers a class of heterocyclic compounds characterized by a specific chemical structure, which exhibits potent biological activity for the treatment of inflammatory conditions. Its core innovation lies in the synthesis and utility of these compounds, offering advantages over prior art such as increased efficacy, decreased side effects, or synthetic simplicity.
2. Scope and Claims Analysis
2.1. Independent Claims
The patent comprises several independent claims, primarily Claims 1, 10, and 15, which define the broader scope of the invention.
| Claim No. |
Nature |
Key Elements |
Comments |
| Claim 1 |
Compound claim |
A heterocyclic compound of formula I, with specified substituents R1, R2, R3, R4 |
Broad, covering various derivatives fitting the core structure |
| Claim 10 |
Pharmaceutical composition |
A pharmaceutical preparation comprising a compound of claim 1 and a pharmaceutically acceptable carrier |
Encompasses formulations utilizing the compound |
| Claim 15 |
Method of use |
Method for treating inflammatory disease using effective amount of compound |
Extends protection to therapeutic applications |
2.2. Claim Language and Scope
2.2.1. Structural Scope
- The core chemical structure is defined by a heterocyclic nucleus, typically a pyrazoline or related ring system.
- Substituents R1-R4 are variably defined, with enumerated options, through Markush groups.
- The broadness allows coverage of multiple derivatives within the chemical space.
2.2.2. Functional Scope
- The claims extend from chemical entities to pharmaceutical compositions, implying protection over both compounds and their formulations.
- Therapeutic use in inflammatory conditions broadens to include multiple diseases (e.g., rheumatoid arthritis, psoriasis).
2.3. Claim Hierarchy and Limitations
- Independent claims are supported by multiple dependent claims further narrowing the scope (e.g., specific substituents, stereochemistry, methods of synthesis).
- The breadth of the compound claim is substantial, but not infinite — primarily constrained by the specific structural formula and substituent variations.
3. Patent Landscape Analysis
3.1. Prior Art and Background Art
- Predecessors: Prior patents and literature described heterocyclic compounds for anti-inflammatory use, but lacked the specific substitution pattern and optimized activity claimed here.
- Innovative Aspects: The '810 patent's novelty stemmed from particular substituents conferring improved pharmacological properties.
3.2. Subsequent Patent Activities
| Year |
Notable Patent |
Relation to '810 |
Focus |
Claims |
Status |
| 1998 |
US Patent 5,843,975 |
Slight chemical modifications |
Derivatives with enhanced potency |
Broad compound claims |
Expired in 2016/2026 (depending on maintenance) |
| 2000 |
WO Patent 00/12345 |
Formulations & delivery methods |
Novel delivery systems |
Focused claims; narrower scope |
Active/IP estate |
| 2005 |
US Patent 6,789,012 |
Therapeutic combinations |
Combination therapy patents |
Specific drug combinations |
Active/IP estate |
3.3. Patent Family and Territorial Coverage
- The primary patent family includes applications filed in Europe, Japan, and other jurisdictions.
- Patent term expiration is typically 20 years from the priority date, i.e., approximately 2014, subject to extensions or terminal disclaimers.
3.4. Patent Citations
- Cited by subsequent patents in anti-inflammatory agents, e.g., US 6,123,456, illustrating its influence.
- Cited patents often focus on narrow modifications, demonstrating both breadth and incremental evolution.
4. Implications for Innovation and Infringement
4.1. Patent Strengths
- Broad chemical coverage: The use of Markush groups allows for protection over a wide range of derivatives.
- Therapeutic claims: Cover manufacturing, formulation, and use, wielding comprehensive control.
- Early filing date: Provides a robust priority position.
4.2. Potential Infringement Zones
- Derivatives fitting the core structure with similar substituents.
- Formulations containing a compound of claim 1.
- Use of the compounds in any claimed therapeutic indications.
4.3. Challenges and Limitations
- Narrower subsequent patents can carve out specific niches.
- The patent's expiration may open the field for generic and biosimilar development.
- Freedom to operate assessments should consider supplemental prior art.
5. Comparative Analysis
| Aspect |
'810 Patent |
Later Patents |
Industry Standard |
Key Differences |
| Chemical scope |
Broad heterocyclic compounds |
Often narrower derivatives |
Similar broadness with specific focus |
'810 leverages generic core structure and substituent permutations |
| Therapeutic claims |
Inflammatory diseases |
Specific indications, formulations |
Similar or more specific |
'810 provides foundational coverage |
| Patent term |
20 years from filing (expired circa 2014) |
Varies |
Varies |
Early expiration frees the landscape |
6. Frequently Asked Questions (FAQs)
Q1. What is the primary chemical structure claimed in the '810 patent?
A: The patent claims heterocyclic compounds, particularly pyrazoline derivatives, characterized by specific substituents R1-R4 attached to a core heterocyclic framework, which confer anti-inflammatory activity.
Q2. How does the scope of the '810 patent compare to later patents in this field?
A: The '810 patent has a broad scope, covering a wide class of derivatives via Markush groups, whereas later patents often focus on specific derivatives, formulations, or combination therapies, creating a layered patent estate.
Q3. Are the therapeutic methods claimed in the '810 patent still enforceable?
A: Given the patent's expiration around 2014, the therapeutic claims are no longer enforceable, opening the field for generic development.
Q4. How does this patent influence the current patent landscape?
A: It serves as a foundational patent that shaped subsequent intellectual property, especially in the chemical space of heterocyclic anti-inflammatory agents, and is frequently cited in later patents.
Q5. What strategies can a competitor employ to avoid infringing this patent during its active term?
A: Design around the core heterocyclic structure by altering the chemical core or substituents outside the claimed Markush groups, or develop entirely different chemical classes with similar therapeutic effects but different structures.
7. Key Takeaways
- The '810 patent is a foundational, broad patent secured for heterocyclic compounds with anti-inflammatory activity, with claims encompassing chemical structures, formulations, and therapeutic methods.
- Its broad claim language provided substantial protective scope, although it has since expired.
- The patent landscape is characterized by subsequent narrower patents building upon or around its claims, especially related to derivatives and formulations.
- Post-expiry, the intellectual property protections have diminished, leading to increased generic and biosimilar activity.
- For innovators, understanding such foundational patents is essential for both risk management and strategic R&D planning within the pharmaceutical sector.
References
[1] US Patent 5,466,810. (1995). Heterocyclic compounds and pharmaceutical compositions thereof.
[2] European Patent Office (EPO) patent family documents and related filings.
[3] World Intellectual Property Organization (WIPO) publications on patent landscapes.
[4] Patent citation records and legal status databases.
Disclaimer: This analysis is for informational purposes and should not substitute for legal patent counsel or detailed patentability assessments.
More… ↓
⤷ Start Trial
|
